T1 mapping of the gadolinium-enhanced myocardium: adjustment for factors affecting interpatient comparison - PubMed (original) (raw)
. 2011 May;65(5):1407-15.
doi: 10.1002/mrm.22716. Epub 2010 Dec 16.
Affiliations
- PMID: 21500267
- PMCID: PMC3092826
- DOI: 10.1002/mrm.22716
T1 mapping of the gadolinium-enhanced myocardium: adjustment for factors affecting interpatient comparison
Neville Gai et al. Magn Reson Med. 2011 May.
Abstract
Quantitative T(1) mapping of delayed gadolinium-enhanced cardiac magnetic resonance imaging has shown promise in identifying diffuse myocardial fibrosis. Despite careful control of magnetic resonance imaging parameters, comparison of T(1) times between different patients may be problematic because of patient specific factors such as gadolinium dose, differing glomerular filtration rates, and patient specific delay times. In this work, a model driven approach to account for variations between patients to allow for comparison of T(1) data is provided. Kinetic model parameter values were derived from healthy volunteer time-contrast curves. Correction values for the factors described above were used to normalize T(1) values to a matched state. Examples of pre- and postcorrected values for a pool of normal subjects and in a patient cohort of type 1 diabetic patients shows tighter clustering and improved discrimination of disease state.
Trial registration: ClinicalTrials.gov NCT00360815 NCT00360893.
Copyright © 2010 Wiley-Liss, Inc.
Figures
FIG. 1
Example of multiphase images obtained from a volunteer. a: Source images obtained using an inversion recovery True FISP Look Locker sequence in the four chamber view with FOV = 380 × 297 mm, matrix size = 192 × 75, slice thickness = 8 mm, TR/TE = 2.5/1.1 msec, phase interval = 23 msec, flip angle = 50°. b: Myocardial wall contouring. c: _T_1 fitting over the entire myocardium.
FIG. 2
Precontrast _T_1 values of the myocardium showed a strong negative linear correlation to heart rate (Pearson r = −0.89).
FIG. 3
Correction curves for changing dose (dose = 0.1 to 0.28 mmol/kg) and for different delay times after the injection of gadolinium. The correction factor on the _y_-axis is in reference to a gadolinium dose of 0.15 mmol/kg.
FIG. 4
Correction curves for varying time and as a function of different doses of gadolinium. The correction factor on the _y_-axis is in reference to a standardized delay time of 15 min after gadolinium injection.
FIG. 5
Correction for varying GFR at different time values. The correction factor on the _y_-axis is in reference to _m_2 = 0.0064 min−1 (corresponding to GFR = 90 mL/min/1.73 m2 for weight = 70 kg and height =175 cm).
FIG. 6
Correction for hematocrit fraction variation for different time values. The correction factor on the _y_-axis is in reference to a hematocrit level of 0.40.
FIG. 7
_T_1 values for low- and high-cardiovascular risk diabetic patients before and after normalization. (*p < 0.05 for difference after normalization). Before normalization, gadolinium dose ranged from 0.1 mmol/kg to 0.22 mmol/kg, delay time from 8 to 16 min, and GFR from 64.8 to 114.1 mL/min/1.73 m2. Data were normalized to a dose of 0.15 mmol/kg, delay time of 15 min, and _m_2 = 0.0064 min−1 (GFR = 90 mL/min/1.73 m2 for weight = 70 kg and height = 175 cm).
Similar articles
- T1 mapping of the myocardium: intra-individual assessment of post-contrast T1 time evolution and extracellular volume fraction at 3T for Gd-DTPA and Gd-BOPTA.
Kawel N, Nacif M, Zavodni A, Jones J, Liu S, Sibley CT, Bluemke DA. Kawel N, et al. J Cardiovasc Magn Reson. 2012 Apr 28;14(1):26. doi: 10.1186/1532-429X-14-26. J Cardiovasc Magn Reson. 2012. PMID: 22540153 Free PMC article. - Dose correction for post-contrast T1 mapping of the heart: the MESA study.
Gai ND, Sandfort V, Liu S, Lima JAC, Bluemke DA. Gai ND, et al. Int J Cardiovasc Imaging. 2016 Feb;32(2):271-279. doi: 10.1007/s10554-015-0754-3. Epub 2015 Sep 11. Int J Cardiovasc Imaging. 2016. PMID: 26362875 Free PMC article. - Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping.
Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta SN, Kaye DM, Taylor AJ. Iles L, et al. J Am Coll Cardiol. 2008 Nov 4;52(19):1574-80. doi: 10.1016/j.jacc.2008.06.049. J Am Coll Cardiol. 2008. PMID: 19007595 - Association of myocardial fibrosis and cardiovascular events: the multi-ethnic study of atherosclerosis.
Ambale-Venkatesh B, Liu CY, Liu YC, Donekal S, Ohyama Y, Sharma RK, Wu CO, Post WS, Hundley GW, Bluemke DA, Lima JAC. Ambale-Venkatesh B, et al. Eur Heart J Cardiovasc Imaging. 2019 Feb 1;20(2):168-176. doi: 10.1093/ehjci/jey140. Eur Heart J Cardiovasc Imaging. 2019. PMID: 30325426 Free PMC article. - T1 mapping of the myocardium: intra-individual assessment of the effect of field strength, cardiac cycle and variation by myocardial region.
Kawel N, Nacif M, Zavodni A, Jones J, Liu S, Sibley CT, Bluemke DA. Kawel N, et al. J Cardiovasc Magn Reson. 2012 May 1;14(1):27. doi: 10.1186/1532-429X-14-27. J Cardiovasc Magn Reson. 2012. PMID: 22548832 Free PMC article.
Cited by
- Comparison of Methemoglobin, Deoxyhemoglobin, and Ferrous Nitrosyl Hemoglobin as Potential MRI Contrast Agents.
Ayati R, Manwaring KC, Allen SP, Day RW, Lewis RS. Ayati R, et al. Ann Biomed Eng. 2023 Sep;51(9):2013-2020. doi: 10.1007/s10439-023-03226-w. Epub 2023 Jun 3. Ann Biomed Eng. 2023. PMID: 37270456 Free PMC article. - Guanidinium and amide CEST mapping of human brain by high spectral resolution CEST at 3 T.
Wang K, Park S, Kamson DO, Li Y, Liu G, Xu J. Wang K, et al. Magn Reson Med. 2023 Jan;89(1):177-191. doi: 10.1002/mrm.29440. Epub 2022 Sep 5. Magn Reson Med. 2023. PMID: 36063502 Free PMC article. - Quantitative MRI of chronic pancreatitis: results from a multi-institutional prospective study, magnetic resonance imaging as a non-invasive method for assessment of pancreatic fibrosis (MINIMAP).
Tirkes T, Yadav D, Conwell DL, Territo PR, Zhao X, Persohn SA, Dasyam AK, Shah ZK, Venkatesh SK, Takahashi N, Wachsman A, Li L, Li Y, Pandol SJ, Park WG, Vege SS, Hart PA, Topazian M, Andersen DK, Fogel EL; Consortium for the Study of Chronic Pancreatitis, Diabetes, Pancreatic Cancer (CPDPC). Tirkes T, et al. Abdom Radiol (NY). 2022 Nov;47(11):3792-3805. doi: 10.1007/s00261-022-03654-7. Epub 2022 Aug 29. Abdom Radiol (NY). 2022. PMID: 36038644 Free PMC article. - T1 values and extracellular volume fraction in asymptomatic subjects: variations in left ventricular segments and correlation with cardiovascular risk factors.
Kim MY, Cho SJ, Kim HJ, Kim SM, Lee SC, Paek M, Choe YH. Kim MY, et al. Sci Rep. 2022 Jul 22;12(1):12544. doi: 10.1038/s41598-022-16696-0. Sci Rep. 2022. PMID: 35869106 Free PMC article. - Left Ventricular Structure, Tissue Composition, and Aortic Distensibility in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications.
Turkbey EB, Backlund JC, Gai N, Nacif M, van der Geest RJ, Lachin JM, Armstrong A, Volpe GJ, Nazarian S, Lima JAC, Bluemke DA; DCCT/EDIC Research Group. Turkbey EB, et al. Am J Cardiol. 2022 Jul 1;174:158-165. doi: 10.1016/j.amjcard.2022.03.036. Epub 2022 Apr 29. Am J Cardiol. 2022. PMID: 35501170 Free PMC article. Clinical Trial.
References
- Kim RJ, Chen EL, Lima JA, Judd RM. Myocardial Gd-DTPA kinetics determine MRI contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction. Circulation. 1996;94:3318–3326. - PubMed
- Kim RJ, Hillenbrand HB, Judd RM. Evaluation of myocardial viability by MRI. Herz. 2000;25:417–430. - PubMed
- Thomson LE, Kim RJ, Judd RM. Magnetic resonance imaging for the assessment of myocardial viability. J Magn Reson Imaging. 2004;19:771–788. - PubMed
- Wagner A, Mahrholdt H, Holly TA, Elliott MD, Regenfus M, Parker M, Klocke FJ, Bonow RO, Kim RJ, Judd RM. Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. Lancet. 2003;361:374–379. - PubMed
- Wu E, Judd RM, Vargas JD, Klocke FJ, Bonow RO, Kim RJ. Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction. Lancet. 2001;357:21–28. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- ZIA CL090019-01/ImNIH/Intramural NIH HHS/United States
- ZIA EB000072/ImNIH/Intramural NIH HHS/United States
- N01-DK-6-2204/DK/NIDDK NIH HHS/United States
- ZIA EB000072-03/ImNIH/Intramural NIH HHS/United States
- ZIA EB000072-01/ImNIH/Intramural NIH HHS/United States
- UL1 RR025014/RR/NCRR NIH HHS/United States
- Z99 CL999999/ImNIH/Intramural NIH HHS/United States
- ZIA CL090019-02/ImNIH/Intramural NIH HHS/United States
- ZIA CL090019/ImNIH/Intramural NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical